Loading clinical trials...
Loading clinical trials...
The purpose of this study is to learn about the safety and effectiveness of BESPONSA. BESPONSA is approved for treatment of relapsed or refractory CD22-positive acute lymphocytic leukemia. Registrati...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Pfizer
NCT06481735 · Acute Lymphocytic Leukemia
NCT05442515 · B-NHL, B-Non Hodgkin Lymphoma, and more
NCT06316856 · T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, and more
NCT07070219 · Acute Lymphocytic Leukemia Refractory, Lymphoma, Lymphoblastic
NCT03934372 · Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, and more
Pfizer
Tokyo
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions